Dianthus Therapeutics

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 2015-01-01

Employees: 53

Market Cap: -

Website: https://www.magentatx.com

Introduction: Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

Clinical Trials

Active:1

Completed:1

Trial Phases

3 Phases

Phase 1:1

Phase 2:3

Phase 3:1

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials

Phase 2

3 (60.0%)

Phase 1

1 (20.0%)

Phase 3

1 (20.0%)

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

Phase 3

Recruiting

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy

Interventions: Drug: DNTH103
Drug: Placebo

First Posted Date: 2025-03-05

Last Posted Date: 2025-08-19

Lead Sponsor: Dianthus Therapeutics

Target Recruit Count: 480

Registration Number: NCT06858579

Locations: 🇷🇸
Clinical Study Site, Kragujevac, Serbia
🇺🇸
Texas Locations, Houston, Texas, United States

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

Phase 2

Recruiting

Conditions: Multifocal Motor Neuropathy

Interventions: Drug: Placebo
Drug: DNTH103

First Posted Date: 2024-08-05

Last Posted Date: 2025-07-23

Lead Sponsor: Dianthus Therapeutics

Target Recruit Count: 36

Registration Number: NCT06537999

Locations: 🇵🇱
Clinical Study Site, Katowice, Poland

A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)

Phase 2

Active, not recruiting

Conditions: Myasthenia Gravis, Generalized

Interventions: Drug: Placebo
Drug: DNTH103

First Posted Date: 2024-02-28

Last Posted Date: 2025-07-23

Lead Sponsor: Dianthus Therapeutics

Target Recruit Count: 65

Registration Number: NCT06282159

Locations: 🇸🇪
Clinical Study Site, Malmö, Sweden
🇺🇸
Clincal Study Site, Tampa, Florida, United States
🇺🇸
Clinical Study Site #2, Houston, Texas, United States

Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB)

Phase 1

Terminated

Conditions: Myelodysplasia
Acute Myeloid Leukemia

First Posted Date: 2022-02-04

Last Posted Date: 2023-02-09

Lead Sponsor: Magenta Therapeutics, Inc.

Target Recruit Count: 22

Registration Number: NCT05223699

Locations: 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Sarah Cannon Research Institute at HealthONE, Denver, Colorado, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 5 locations

A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456

Terminated

Conditions: Inherited Metabolic Disorders (IMD)

First Posted Date: 2019-07-05

Last Posted Date: 2021-03-15

Lead Sponsor: Magenta Therapeutics, Inc.

Target Recruit Count: 3

Registration Number: NCT04008849

Locations: 🇺🇸
University of Minnesota, Minneapolis, Minnesota, United States

News

Commit Biologics Forms Scientific Advisory Board to Advance Complement-Based Cancer and Autoimmune Therapies

3 months ago

Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform.